Dr. Gainor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114Phone+1 617-726-2862
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
- Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
- Harvard Medical SchoolClass of 2008
Certifications & Licensure
- MA State Medical License 2010 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) Start of enrollment: 2020 Apr 23
- Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Start of enrollment: 2015 Oct 01
Roles: Principal Investigator, Contact
- Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination Start of enrollment: 2015 Dec 01
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsHypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.Camila Robles-Oteíza, Katherine Hastings, Jungmin Choi, Isabelle Sirois, Arvind Ravi
The Journal of Experimental Medicine. 2025-01-06 - Spatial biology captures the effects of neoadjuvant chemo-immunotherapy in lung cancer.Jonathan H Chen, Justin F Gainor
Nature Genetics. 2024-12-10 - Immune responses in checkpoint myocarditis across heart, blood and tumour.Steven M Blum, Daniel A Zlotoff, Neal P Smith, Isabela J Kernin, Swetha Ramesh
Nature. 2024-12-01
Press Mentions
- Individualized Cancer Therapy Demonstrates Safety and Sustained Immune ResponsesAugust 8th, 2024
- HER2 and Lung CancerJune 7th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: